Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3214 Carcinoma, Non-Small-Cell Lung 2727 Breast Neoplasms 2550 Colorectal Neoplasms 1461 Prostatic Neoplasms 1307 Neoplasm Metastasis 1300 Multiple Myeloma 1112 Melanoma 1103 Ovarian Neoplasms 1006 Lung Neoplasms 944 Recurrence 924 Leukemia, Myeloid, Acute 879 Pancreatic Neoplasms 832 Lymphoma, Non-Hodgkin 767 Lymphoma 713 Stomach Neoplasms 692 Carcinoma, Renal Cell 660 Carcinoma, Hepatocellular 647 Leukemia, Lymphocytic, Chronic, B-Cell 560 Squamous Cell Carcinoma of Head and Neck 550 Lymphoma, Follicular 515 Head and Neck Neoplasms 490 Glioblastoma 472 Small Cell Lung Carcinoma 447 Lymphoma, Large B-Cell, Diffuse 440 Triple Negative Breast Neoplasms 435 Advanced Solid Tumors 432 Leukemia 426 Uterine Cervical Neoplasms 420 Urinary Bladder Neoplasms 405

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Anal Cancer Metastatic × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡